Biogen [BIIB] vs Johnson & Johnson [JNJ] Detailed Stock Comparison
Biogen
NASDAQ
Loading...
Johnson & Johnson
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Biogen wins in 12 metrics, Johnson & Johnson wins in 7 metrics, with 0 ties. Biogen appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biogen | Johnson & Johnson | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.19 | 19.06 | Biogen |
| Price-to-Book Ratio | 1.15 | 5.45 | Biogen |
| Debt-to-Equity Ratio | 37.40 | 64.69 | Biogen |
| PEG Ratio | 8.27 | 1.06 | Johnson & Johnson |
| EV/EBITDA | 7.50 | 15.21 | Biogen |
| Profit Margin (TTM) | 15.31% | 25.00% | Johnson & Johnson |
| Operating Margin (TTM) | 34.61% | 28.91% | Biogen |
| EBITDA Margin (TTM) | 34.61% | 28.91% | Biogen |
| Return on Equity | 9.13% | 30.21% | Johnson & Johnson |
| Return on Assets (TTM) | 5.62% | 7.61% | Johnson & Johnson |
| Free Cash Flow (TTM) | $2.52B | $18.06B | Johnson & Johnson |
| Dividend Yield | N/A | 2.47% | N/A |
| 1-Year Return | -32.14% | 9.02% | Johnson & Johnson |
| Price-to-Sales Ratio (TTM) | 2.02 | 4.72 | Biogen |
| Enterprise Value | $24.16B | $460.08B | Johnson & Johnson |
| EV/Revenue Ratio | 2.42 | 5.08 | Biogen |
| Gross Profit Margin (TTM) | 77.13% | 67.87% | Biogen |
| Revenue per Share (TTM) | $68 | $38 | Biogen |
| Earnings per Share (Diluted) | $10.45 | $9.33 | Biogen |
| Beta (Stock Volatility) | 0.13 | 0.40 | Biogen |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Biogen vs Johnson & Johnson Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biogen | 0.09% | 3.10% | 13.40% | 9.70% | -1.08% | -7.25% |
| Johnson & Johnson | 0.05% | 2.41% | 8.86% | 16.81% | 10.25% | 24.24% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biogen | -32.14% | -29.95% | -50.57% | -54.19% | 154.80% | 238.90% |
| Johnson & Johnson | 9.02% | 8.92% | 16.46% | 88.01% | 210.64% | 188.88% |
Performance & Financial Health Analysis: Biogen vs Johnson & Johnson
| Metric | BIIB | JNJ |
|---|---|---|
| Market Information | ||
| Market Cap | $20.21B | $428.20B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 1,259,084 | 8,328,860 |
| 90 Day Avg. Volume | 1,387,041 | 8,927,297 |
| Last Close | $139.12 | $178.93 |
| 52 Week Range | $110.04 - $207.59 | $140.68 - $180.61 |
| % from 52W High | -32.98% | -0.93% |
| All-Time High | $480.18 (Mar 16, 2015) | $186.69 (Apr 25, 2022) |
| % from All-Time High | -71.03% | -4.16% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.06% |
| Quarterly Earnings Growth | 0.09% | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.15% | 0.25% |
| Operating Margin (TTM) | 0.35% | 0.29% |
| Return on Equity (TTM) | 0.09% | 0.30% |
| Debt to Equity (MRQ) | 37.40 | 64.69 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $120.29 | $32.61 |
| Cash per Share (MRQ) | $18.82 | $7.84 |
| Operating Cash Flow (TTM) | $2.12B | $23.03B |
| Levered Free Cash Flow (TTM) | $2.27B | $11.08B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 2.47% |
| Last 12-Month Dividend | N/A | $3.72 |
Valuation & Enterprise Metrics Analysis: Biogen vs Johnson & Johnson
| Metric | BIIB | JNJ |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.19 | 19.06 |
| Forward P/E | 8.27 | 16.77 |
| PEG Ratio | 8.27 | 1.06 |
| Price to Sales (TTM) | 2.02 | 4.72 |
| Price to Book (MRQ) | 1.15 | 5.45 |
| Market Capitalization | ||
| Market Capitalization | $20.21B | $428.20B |
| Enterprise Value | $24.16B | $460.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.42 | 5.08 |
| Enterprise to EBITDA | 7.50 | 15.21 |
| Risk & Other Metrics | ||
| Beta | 0.13 | 0.40 |
| Book Value per Share (MRQ) | $120.29 | $32.61 |
Financial Statements Comparison: Biogen vs Johnson & Johnson
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BIIB | JNJ |
|---|---|---|
| Revenue/Sales | $2.43B | $21.89B |
| Cost of Goods Sold | $629.30M | $7.36B |
| Gross Profit | $1.80B | $14.54B |
| Research & Development | $434.10M | $3.23B |
| Operating Income (EBIT) | $625.20M | $6.30B |
| EBITDA | $831.80M | $8.72B |
| Pre-Tax Income | $311.20M | $13.63B |
| Income Tax | $70.70M | $2.63B |
| Net Income (Profit) | $240.50M | $11.00B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BIIB | JNJ |
|---|---|---|
| Cash & Equivalents | $2.60B | $38.47B |
| Total Current Assets | $7.63B | $71.55B |
| Total Current Liabilities | $5.30B | $56.90B |
| Long-Term Debt | $4.87B | $38.36B |
| Total Shareholders Equity | $16.98B | $78.11B |
| Retained Earnings | $19.50B | N/A |
| Property, Plant & Equipment | $6.22B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BIIB | JNJ |
|---|---|---|
| Operating Cash Flow | $518.90M | $6.35B |
| Capital Expenditures | $-37.10M | $-795.00M |
| Free Cash Flow | $212.20M | $3.37B |
| Debt Repayment | $0 | $-2.87B |
| Common Stock Repurchase | N/A | $-2.13B |
Short Interest & Institutional Ownership Analysis
| Metric | BIIB | JNJ |
|---|---|---|
| Shares Short | 3.96M | 17.14M |
| Short Ratio | 2.97 | 2.00 |
| Short % of Float | 0.03% | 0.01% |
| Average Daily Volume (10 Day) | 1,259,084 | 8,328,860 |
| Average Daily Volume (90 Day) | 1,387,041 | 8,927,297 |
| Shares Outstanding | 145.72M | 2.41B |
| Float Shares | 146.23M | 2.40B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.93% | 0.74% |
Dividend Analysis & Yield Comparison: Biogen vs Johnson & Johnson
| Metric | BIIB | JNJ |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.72 |
| Last 12-Month Dividend Yield | N/A | 2.47% |
| 3-Year Avg Annual Dividend | N/A | $3.97 |
| 3-Year Avg Dividend Yield | N/A | 0.75% |
| 3-Year Total Dividends | N/A | $11.92 |
| Ex-Dividend Date | N/A | Feb 18, 2025 |